NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 901–1,000 of 1,000
Jung, H.-J., Kim, J. H., Suh, S., & Baek, W. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5753 · Cited by 2
“Additionally, chaetocin promotes ROS generation and upregu‑ lates antioxidant genes, such as heme oxygenase 1, NAD(P)H quinone dehydrogenase 1, glutamate‑cysteine ligase modifier subunit and thioredoxin reductase 1 (39,40).”
Alves, R., Ventura, F. I. Q. S., Jorge, J., Marques, G., Coucelo, M., Diamond, J., Oliveiros, B., Pereira, A., Freitas-Tavares, P., Almeida, A. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125682 · Cited by 2
Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma
Cai, Y., Wang, J., Zhang, Z., Pan, L., Fang, J., Cui, L. R., Xu, S., Zhang, Y., Pang, J., You, Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1596879 · Cited by 3
Liu, Z.-K., Zhu, J.-Y., Zhou, Q., Qian, H.-Y., & Cui, F.-H. (2026) · Drug development research (Print) · doi:10.1002/ddr.70223 · Cited by 2
Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition
Gebru, M. T., & Stokoe, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1856014 · Cited by 3
“3 NRF2 in cancer: from cytoprotector to oncogenic driver 3.1 Frequency and mechanisms of NRF2 pathway activation in cancer While NRF2’s cytoprotective role is essential in normal physiology, its constitutive activation is a hallmark of many cancers (Sporn and Liby, 2012).”
InfluentialGPX4 in the Tumor Microenvironment: Not Just Inhibiting Ferroptosis, but Immuno-Metabolic Regulation
Li, X., Zhang, M., Xu, Z., Wufuer, R., & Li, W. (2026) · Biomolecules · doi:10.3390/biom16071006 · Cited by 2
“The therapeutic challenge is to selectively inhibit the tumor Nrf2 while maintaining its cytoprotective activity in normal tissues [38,39].”
Brod, J., Demasi, A. P. D., Montalli, V. Â. M., Teixeira, L. N., Furuse, C., de Aguiar, M. C. F., Soares, A. B., Sperandio, M., & de Araújo, V. C. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2218-8 · Cited by 2
Vargas-Mendoza, N., Sandoval-Gallegos, E. M., Madrigal‐Santillán, E., Morales-Martínez, M., Soriano-Ursua, M. A., Ángeles-Valencia, M., Morales‐González, Á., Portillo-Reyes, J., & Morales‐González, J. A. (2021) · Reference series in phytochemistry · doi:10.1007/978-3-030-45299-5_34-1 · Cited by 2
Baenke, F., Dhomen, N. S., Gottlieb, E., & Marais, R. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_28 · Cited by 3
Garzón-Castaño, S. C., Jiménez-González, F. J., Veloza, L. A., & Arias, J. C. (2020) · F1000Research · doi:10.12688/f1000research.26901.1 · Cited by 2
Role of cancer stem cells in developing chemoresistance of solid tumor
Aarthi, V., & Chattopadhyay, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13212-4.00020-9 · Cited by 3
Song, C., Choi, Y., Kim, N., Nam, R. H., Kim, J. W., Jang, J. Y., Kim, E. H., Ha, S., & Lee, H.-N. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.818 · Cited by 6
“NRF2 can promote proliferation and migration of CRC as previously mentioned, and expression of NRF2 even can lead to drug resistance to chemotherapeutic drugs [28,30].”
Li, J., Sun, S., Li, Y., Tian, M., Li, X., Ren, S., Huang, Z., Wang, Y., & Du, S. (2025) · Xenobiotica · doi:10.1080/00498254.2025.2465239 · Cited by 3
“Additionally, its cytoprotective activity can contribute to the development of chemoresistance to cancer drugs (Sporn and liby 2012) (Bai et al. 2016). the Nrf2 pathway has been found to regulate ferroptosis in opposing directions (Hu et al. 2024). typically, mild activation of the Nrf2 pathway…”
Çetinkaya, S., Ayan, İ. Ç., Dursun, H. G., Süntar, I. P., Akça, K. T., Gök, H. N., & Atak, M. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206370057250421061226 · Cited by 4
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
Syu, J.-P., Chi, J., & Kung, H. (2016) · InTech eBooks · doi:10.5772/65105 · Cited by 5
“Nrf2 gets activated in malignant tumors, such as carcinomas of skin, lung, oesophagus, and larynx [58].”
BackgroundValencia, C. A., Kleine, L. L., Velasco, A. M. P., Barreto, A. Y. C., & Díaz, C. E. A. (2018) · Familial Cancer · doi:10.1007/s10689-017-0068-9 · Cited by 2
El-Khodary, M. S. M. (2018) · CellBio · doi:10.4236/cellbio.2018.73004 · Cited by 3
Oxidative Stress and Cancer: Role of the Nrf2-Antioxidant Response Element Signaling Pathway
Ruwali, M., & Shukla, R. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_60-1 · Cited by 2
Role of Stem Cells and Reactive Oxygen Species in Cancer: An Insight into Nrf2 Signaling
Ezhilarasan, D., Perumal, E., Balakrishnan, A., & Anbalagan, M. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_103-1 · Cited by 2
Metabolic dysregulation in cancer progression
Arfin, S., Agrawal, K., Kumar, A., Kumar, A. J., Rathi, B., & Kumar, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99879-6.00008-0 · Cited by 3
Somatic Genome Alterations in Human Lung Cancers
Imielinski, M. B., Hammerman, P. S., Thomas, R. K., & Meyerson, M. M. (2014) · Wiley eBooks · doi:10.1002/9781118468791.ch4 · Cited by 2
Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!
Rupp, N. J., Montironi, R., Mischo, A., & Moch, H. (2017) · European Urology Supplements · doi:10.1016/j.eursup.2017.08.007 · Cited by 4
The Potential Role of Nrf2-PD-L1 Axis in Promoting of Oxaliplatin Resistance in Colon Cancer CellsPreprint
Payandeh, Z., Tazehkand, A. P., Mansoori, B., Khaze, V., Asadi, M., Samadi, N., & Baradaran, B. (2020) · Research Square · doi:10.21203/rs.3.rs-58926/v1 · Cited by 2
“Page 9/25 lung, breast, liver, and endometrium tumors tissues [40,41].”
BackgroundNRF2 inhibition of alveolar macrophage MHC II expression during Mycobacterium tuberculosis infectionPreprint
Pham, L. K., Cervantes, M. M., Lim, P. N., Dubey, D., Tufts, A., Shinkawa, T., Behar, S. M., & Rothchild, A. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.16.670319 · Cited by 2
“…known to regulate many processes including antioxidant production, cell death, and iron sequestration, but not all of its roles are yet appreciated 16– 18,20,51,52 By specifically examining AMs in vitro and in vivo , our study reveals that NRF2 inhibits MHC II expression on Mtb-infected AMs and…”
TBHQ Alleviates Particulate Matter-Induced Pyroptosis in Human Nasal Epithelial Cells
Kim, J., Choi, H., Oh, J., Kim, S. W., Kim, S. W., Kim, B. G., Cho, J. H., Lee, J., & Lee, D. C. (2024) · Toxics · doi:10.3390/toxics12060407 · Cited by 1
“This knowledge may contribute to the development of potential therapeutic agents for various inflammatory diseases.”
BackgroundDevika, T., Ganesapandian, M., Mythili, K., Rao, K. S., Srinivasamurthy, S. K., Biswajit, D., & Shewade, D. G. (2024) · Cureus · doi:10.7759/cureus.64849 · Cited by 4
Amadeo, E., Foti, S., Camera, S., Rossari, F., Persano, M., Prinzi, F. L., Vitiello, F., Gardini, A. C., & Rimini, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377321 · Cited by 1
“Activation of NFR2 or inactivation of KEAP1 can prevent the KEAP1/CUL3 complex-induced ubiquitinoylation of NFR2 [35,36].”
Nasirmahalleh, N. M., Hemmati, M., Biyabani, A., & Pirouz, F. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0170 · Cited by 1
“The expression of antioxidants and detoxifying enzymes is promoted by NRF2, which was originally believed to act as a protective factor against tumorigenesis (Sporn and Liby, 2012).”
Zhu, C., Pang, M., Gong, W., Pang, H., & Qu, H. (2024) · Emerging contaminants · doi:10.1016/j.emcon.2024.100460 · Cited by 1
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
Chetta, M., Bukvić, N., & Rosati, A. (2025) · Viruses · doi:10.3390/v17091166 · Cited by 1
“This not only supports the survival of infected cells but also facilitates viral persistence and progression toward malignancy by promoting an environment resistant to immune-mediated clearance and apoptosis [28].”
Chen, C., Chou, W., Kamineni, V. N., Wu, P.-Y., Zhang, Z., Wu, X., Vulpe, C. D., & Lin, Z. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.127519 · Cited by 1
Cho, M. S., Lee, Y., Kim, K. D., Choi, M., Park, S. Q., Lee, S.-H., Nam, H.-S., & Lee, Y. (2026) · Life · doi:10.3390/life16040615 · Cited by 1
Badi, M. I., Trangadia, B. J., Dhameliya, R. C., Patel, U., & Kalaria, V. A. (2026) · Environmental Toxicology · doi:10.1002/tox.70104 · Cited by 2
Zhao, Z., Lu, H., Zhang, J. Y., Zhao, J., Wang, J., Zhu, T., Xu, S., You, Q., Lu, M., & Jiang, Z. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00096 · Cited by 1
Pham, L. K., Cervantes, M. M., Lim, P. N., Dubey, D., Tufts, A., Mitchell, M. C., Shinkawa, T., Behar, S. M., & Rothchild, A. C. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117397 · Cited by 5
“…is known to regulate many processes including antioxidant production, cell death, and iron sequestration, but not all functions are yet appreciated 16–18, 20 ,58, 59 By specifically examining AMs, our study reveals that NRF2 inhibits MHC II expression on Mtb-infected Mtb-infected AMs by Overall,…”
Khan, M. S., Zafar, I., & Bopassa, J. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146329 · Cited by 2
Kashyap, C. K., Kumar, S., & Sharma, S. (2026) · Plant Science · doi:10.1016/j.plantsci.2026.113331 · Cited by 1
Nrf2 gene as a double-edged sword: Clinical relevance of its genetic polymorphisms
Ishikawa, T., Shinkai, M., & Kaneko, T. (2016) · Integrative Molecular Medicine · doi:10.15761/imm.1000225 · Cited by 2
“In fact, mutations in the Nrf2 and Kea1 genes have been found in carcinomas of the lung [60], breast [61], liver [62], and stomach [62].”
BackgroundDiscovery and Development of Keap1-Nrf2 Protein-Protein Interaction Inhibitors
Jiang, Z., & You, Q. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_10 · Cited by 1
Tissue Repair: Guarding against Friendly Fire
Hiebert, P., & Werner, S. (2019) · Current Biology · doi:10.1016/j.cub.2019.09.073 · Cited by 1
Prasetya, H., Dewi, F. R. P., & Setiawan, B. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1374/1/012055 · Cited by 1
Suliman, N., & Balla, O. (2020) · Scholars Academic Journal of Biosciences · doi:10.36347/sajb.2020.v08i07.004 · Cited by 1
“cells become resistant to treatment [5-7].”
Targeting Natural Compounds to Mitochondria as a Novel Strategy for Cancer Therapy
Checker, R., Pal, D., Sharma, D., & Sandur, S. K. (2021) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_186-1 · Cited by 1
Network-Based Identification of Module Biomarker Associated with Hepatocellular Carcinoma
Hussain, T., Singh, P. K., Kumar, A., Ahmad, N., Dohare, R., & Sankhwar, S. (2022) · Communications in computer and information science · doi:10.1007/978-3-030-95502-1_12 · Cited by 1
Oxidative Stress and Cancer: Role of the Nrf2-Antioxidant Response Element Signaling Pathway
Ruwali, M., & Shukla, R. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_60 · Cited by 2
Vargas-Mendoza, N., Sandoval-Gallegos, E. M., Madrigal‐Santillán, E., Morales-Martínez, M., Soriano-Ursua, M. A., Ángeles-Valencia, M., Morales‐González, Á., Portillo-Reyes, J., & Morales‐González, J. A. (2022) · Reference series in phytochemistry · doi:10.1007/978-3-030-78160-6_34 · Cited by 2
López-Sánchez, M., García‐Rodríguez, M. D. C., Aguayo‐Ortiz, R., Cruz, E. Y. H., Figueroa‐Figueroa, D. I., & Hernández‐Luis, F. (2023) · ChemMedChem · doi:10.1002/cmdc.202300184 · Cited by 1
USP37 as a novel regulator of NRF2 protein stability and chemoresistance in HCC
Zhang, S., Ding, F., Jia, F., & Lu, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-01913-9 · Cited by 1
Barker, E. C. (2015) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Waters, D. J., & Chiang, E. C. (2019) · Acta Scientifci Nutritional Health · doi:10.31080/asnh.2019.03.0450 · Cited by 1
Oliveira, R. D. S., Silva, W. M., Prati, W. J., Rufino, P. C. H., Santana, R. P. D. V. F., Bassoli, B. K., & da Silva, F. C. (2020) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2020v66n1.428 · Cited by 3
Castaño, S. C. G., Jiménez-González, F. J., Veloza, L. A., & Arias, J. C. (2020) · F1000Research · doi:10.12688/f1000research.26901.2 · Cited by 1
Sayed, L. H., Mohamed, H., Abd‐Elghaffar, S. K., & Badr, G. (2022) · Assiut University Journal of Multidisciplinary Scientific Research · doi:10.21608/aunj.2022.134540.1008
“Nrf-2 plays a key function in avoiding the formation of oxidative stress through up-regulation of the Nrf2-related antioxidants [36, 37].”
BackgroundInhibition of BRD4 Attenuates Inflammation and Oxidative Stress in Retina
Eichenbaum, J. W. (2022) · World Journal of Ophthalmology & Vision Research · doi:10.33552/wjovr.2022.04.000584
Azan, N. K. B., Ng, A. S., Samsudi, F. B., Mazlan, M. R. B., Loh, Y. K., & Ling, M. H. (2023) · Acta Scientifci Nutritional Health · doi:10.31080/asnh.2023.07.1193
Abdel‐Magid, A. F. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00181 · Cited by 1
Fox, D. B., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/513994 · Cited by 1
It’s far better to be alone than to be in bad company
Duruisseaux, M., & Cadranel, J. L. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.02.65
Genetic Alterations of Esophageal Squamous Cell Carcinoma in Korean PatientsPreprint
Park, S., Won, D., Kim, D. J., Park, S. Y., & Lee, S. (2021) · Research Square · doi:10.21203/rs.3.rs-1014087/v1 · Cited by 2
Liu, J., Abudula, A., Yang, H.-T., Xu, L., Bai, G., Tulahong, A., & Eli, M. (2021) · Research Square · doi:10.21203/rs.3.rs-1078211/v1 · Cited by 1
Ramesh, P. S., Bovilla, V. R., Swamy, V. H., Manoli, N. N., Dasegowda, K. B., Siddegowda, S. M., Chandrashekarappa, S., Somasundara, V. M., Devegowda, D., & Thimmulappa, R. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1504099/v1 · Cited by 1
NRF2 suppression increases the susceptibility of hepatocellular carcinoma cancer cells to paclitaxelPreprint
Maghsoudi, M., Khalaj‐Kondori, M., Safaei, S., Amini, M. A., Doustvandi, M. A., Hasani, S., Riazi, N., & Baradaran, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2364075/v1 · Cited by 1
Ramchandani, D. M., Modi, C. M., Patel, P. M., Patel, H. B., Patel, U. D., Paida, B. V., & Patel, H. R. (2023) · Research Square · doi:10.21203/rs.3.rs-3254429/v1 · Cited by 1
Role of Antioxidant Therapy in Respiratory Disease Management
Bhattacharya, B., Devi, N., Sanshita, S., Sharma, A., Puri, V., Kumar, S., Sindhu, R. K., & Singh, I. (2024) · Wiley eBooks · doi:10.1002/9781394270576.ch7 · Cited by 1
Sarlak, S. (2021) · theses.fr (ABES) · doi:10.70675/2e2c5420z3a1fz49c3zb548z8e72b24a52b2 · Cited by 1
Fight Back: Adaptive Responses to Toxicant Exposure
Burcham, P. C. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5553-9_5
The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs
Benito, J., Konopleva, M. Y., & Wilson, W. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_35
“2010), suggesting the potential for PR-104 to exploit the upregulation of AKR1C3 via the activated Nrf2/Keap1/ARE transcriptional response in some tumors (Sporn and Liby 2012).”
BackgroundInflammation and Lung Cancer: Molecular Pathology
Kadara, H. N., Franklin, W. A., & Wistuba, I. I. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2724-1_3
“Basally, NRF2 is kept inactive through binding to its inhibitor Kelch-like ECH-associated protein 1 ( KEAP1) that causes NRF2 degradation [93].”
BackgroundResultInfluentialThe role of microRNAs during endoplasmic reticulum stress induced cell death
Cawley, K. (2012) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/17487
Inflammation and Lung Cancer: Prevention
Bauer, A. K., Miller, Y. E., & Keith, R. L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2724-1_4
Chemopreventive activity of tocopherols in mammary tumorigenesis
Smolarek, A. K. (2013) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3f47mtc
“While at pre-malignant and early malignancy, the role of Nrf2 is still unclear [414].”
BackgroundInfluentialDiehl, K., Bauer, I., Witt-Ramdohr, M., Deisinger, F., Sebens, S., & Schäfer, H. (2015) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0035-1559217
Exome sequencing and human disease : the molecular characterisation of genetic disorders
Walsh, D. M. (2016) · University of Birmingham Institutional Research Archive (University of Birmingham)
Election 2016: Voting on Variants
Cho, R. J., & Collisson, E. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0559
Investigation into the Role of Antioxidants in Tumorigenesis
Harris, I. S. (2014) · Library and Archives Canada (Government of Canada)
Síndrome de leiomiomatosis hereditaria y cáncer de células renales: revisión de la literatura
Valencia, C. A., & Díaz, C. E. A. (2017) · Revista Urología Colombiana / Colombian Urology Journal · doi:10.1016/j.uroco.2017.03.013
Huang, B. K., Langford, T. F., & Sikes, H. D. (2016)
Characteristics and Unmet Clinical Needs Related to Hepatocellular Carcinoma
Newson, J. L., Kinachtchouk, N., Schachtschneider, K. M., Schwind, R. M., & Schook, L. B. (2017) · Digestive Disease Interventions · doi:10.1055/s-0037-1603812
Metabolism: The Sweet Spot in Melanoma Precision Medicine?
Baenke, F., Dhomen, N. S., Gottlieb, E., & Marais, R. (2017) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_28-1
The role of peroxisome proliferator-activated receptor β/δ in colorectal cancer
Tan, E. H. P. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/74230
Hit-to-Lead in Academia: Discovery of a Protein-Protein Interaction Inhibitor of Keap1-Nrf2
Yasuda, D., Obata, R., Takahashi, K., Ohe, T., & Mashino, T. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00211-5
Total quality management (tqm) and systems thinking in translational science
Smith, R. E. F. (2018) · Journal of Translational Science · doi:10.15761/jts.1000244
“So, there is a clinical trial underway, called Metformin in Longevity Study (MILES) [18] and another that is being planned called Targeting Aging with Metformin, or TAME, that will look at the effects of metformin on longevity [12].”
BackgroundSaw, C. L. L. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0163-0
“While the Bdark sides^ of Nrf2 in cancer cannot be ignored, evidences show that mutations occur in Nrf2 or its inhibitor Keap1 [57].”
BackgroundInfluentialSulforaphane and Its Relationship with the Intestinal Flora
Dosieah, P., Tan, L., & Zhenyu, Z. (2018) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2018.10194
“Similar related impacts have been approached in other various studies correlated with vivo and it has been concluded that sulforaphane shows a high tendency to be a direct cause of phase two enzyme in experimental under the sulforaphane intake for several days with high amounts that may reach 1000 mml/kg [26,27, 28].”
BackgroundBaldo, F. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.36962
Targeting Antioxidant Systems to Treat Pancreatic Cancer
Fazzari, F. G. T. (2018) · TSpace (University of Toronto)
Kamai, T., Abe, H., Murakami, S., Kuroda, H., Jamiyan, T., Arai, K., & Yoshida, K. (2019)
Donquiles, C. G. (2018) · Buleria (Universidad de León) · doi:10.18002/10612/9590
Cell Metabolism in Cancer: An Energetic Switch
de Castro, I. P. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-11812-9_6 · Cited by 2
Increasing Chemosensitivity in Colorectal Cancer
Agro, L. A. (2019) · TSpace (University of Toronto)
Akın, D. F., & Kankılıç, T. (2019) · Biology Bulletin · doi:10.1134/s1062359019060050
Pölönen, P. (2013) · UEF eRepo (University of Eastern Finland)
Liu, C., Wang, D., Li, L., & Zhang, R. (2021) · Research Square · doi:10.21203/rs.3.rs-150859/v1
“Constitutive activation of Nrf2-ARE shields malignant cells from oxidative damages [23, 24].”
BackgroundTumor metabolic reprogramming in therapeutic resistance
Siegel, P. M., & Ursini‐Siegel, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00005-x · Cited by 1
Molecular mechanisms of lung cancer
Лосев, О. Э., Бородулин, В. Б., Юрьевна, Р. Н., Бобылева, Е. В., & Владимирович, Б. Я. (2021) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2021.01.124-132 · Cited by 2
“Поэтому для профилактики рака усиление активности Nrf2 остается важным подходом, тогда как для лечения рака желательно ингибирование Nrf2 [51, 60].”
Patel, U. N., Patel, U. D., Kadayata, A. V., Vaja, R. K., Modi, C. M., & Patel, H. B. (2021) · Research Square · doi:10.21203/rs.3.rs-840262/v1
Molecular hydrogen as a nutraceutical for extending the health span
Tarnava, A., & LeBaron, T. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819815-5.00019-7
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.